Towa Hits Profit Target Three Months Early
Nine-Month Results See Towa Meet Annual Operating Profit Goal
Japan’s Towa has almost achieved its full-year operating profit goal in the first nine months of its financial year thanks to lower costs.
You may also be interested in...
Japan’s Towa has completed its €329m deal for the Pensa Investments generics business of Spain’s Esteve.
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.
Belgian off-patent industry association Medaxes has set out its aspirations for a new biosimilars taskforce that has been set up by local health insurance body INAMI. Data cited by the industry body shows that biosimilar penetration in Belgium is still lagging behind that of its European neighbors.